Document Detail


Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy.
MedLine Citation:
PMID:  18620855     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Retrospective analysis of characteristics and outcome of germ cell tumour (GCT) patients with cerebral metastases (CM) undergoing high-dose chemotherapy (HD-CTX) or relapsing with CM. PATIENTS AND METHODS: Patients initially presenting with CM (N=50 pts) or at first relapse (n=19 pts) after primary HD-CTX (434 pts) were analysed. RESULTS: Patients with primary CM (N=50) had elevated ss-human chorion gonadotropin (ss-HCG) in 88% and lung metastases in 90%. Eighty six percent responded to HD-CTX and 40% underwent CNS radiotherapy. Forty four percent achieved long-term survival after primary and 16% after salvage treatment (60% in total). All patients relapsing with CM (n=19) presented initially with ss-HCG-elevation and pulmonary metastases. Treatment consisted of CTX in 78%, irradiation in 90% and surgery in 63%. Twenty six percent achieved long-term survival. CONCLUSION: An interdisciplinary approach of HD-CTX, radiotherapy and surgery leads to long-term survival in 60% of patients with CM at initial diagnosis and 26% relapsing with CM.
Authors:
K Oechsle; C Kollmannsberger; F Honecker; I Boehlke; C Bokemeyer
Related Documents :
3542345 - Short-course drug therapy for tuberculosis.
16856085 - Combination chemotherapy for high-risk gestational trophoblastic tumour.
21594665 - Evaluation of the association of pik3ca mutations and pten loss with efficacy of trastu...
2836935 - Present concepts in the treatment of wilms' tumor.
17950765 - External-beam co-60 radiotherapy for canine nasal tumors: a comparison of survival by t...
16873435 - Correlation between tumor response to first-line chemotherapy and prognosis in advanced...
Publication Detail:
Type:  Journal Article     Date:  2008-07-10
Journal Detail:
Title:  European journal of cancer (Oxford, England : 1990)     Volume:  44     ISSN:  1879-0852     ISO Abbreviation:  Eur. J. Cancer     Publication Date:  2008 Aug 
Date Detail:
Created Date:  2008-08-07     Completed Date:  2008-10-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9005373     Medline TA:  Eur J Cancer     Country:  England    
Other Details:
Languages:  eng     Pagination:  1663-9     Citation Subset:  IM    
Affiliation:
Department of Oncology, University Medical Center Eppendorf, Hamburg, Germany. k.oechsle@uke.hamburg.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antineoplastic Agents / administration & dosage*
Brain Neoplasms* / drug therapy,  radiotherapy,  secondary,  surgery
Cisplatin / administration & dosage
Clinical Trials, Phase II as Topic
Combined Modality Therapy / methods
Humans
Lung Neoplasms / secondary
Male
Middle Aged
Multicenter Studies as Topic
Neoplasm Recurrence, Local
Neoplasm Staging
Neoplasms, Germ Cell and Embryonal* / drug therapy,  radiotherapy,  secondary,  surgery
Prognosis
Retrospective Studies
Salvage Therapy / methods
Stem Cell Transplantation
Survival Analysis
Testicular Neoplasms*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 15663-27-1/Cisplatin
Comments/Corrections
Comment In:
Eur J Cancer. 2008 Aug;44(12):1622-4   [PMID:  18653329 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Urban observatories opportunities for environmental monitoring: solid wastes.
Next Document:  Synthesis and biological evaluation of a focused library of beauveriolides.